TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas
Authors Zhao S, Sun M, Meng H, Ji H, Liu Y, Zhang M, Li H, Li P, Zhang Y, Zhang Q
Received 28 January 2019
Accepted for publication 30 April 2019
Published 23 May 2019 Volume 2019:11 Pages 4743—4756
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Shu Zhao,1,* Mengqi Sun,1,* Hongxue Meng,2 Hongfei Ji,3 Yupeng Liu,4 Minghui Zhang,1 Hongbin Li,1 Pengfei Li,5 Yue Zhang,1 Qingyuan Zhang1
1Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, People’s Republic of China; 2Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, People’s Republic of China; 3Heilongjiang Cancer Research and Prevention Institute, Harbin, Heilongjiang, People’s Republic of China; 4Department of Epidemiology, School of Public Health, Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China; 5Medical Imaging Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, People’s Republic of China
*These authors contributed equally to this work
Background: Toll-like receptor 4 (TLR4), a member of the pattern recognition receptors, has been reported to be involved in carcinogenesis. However, the clinical impact of TLR4 in peripheral T-cell lymphomas (PTCL) remains unclear.
Methods: The current study, using immunohistochemical staining, first examined TLR4 and programmed cell death-ligand 1 (PD-L1) expression in patients with PTCL, to correlate TLR4 and PD-L1 expression with clinicopathological parameters.
Results: It was found that the rates of high expression of TLR4 and PD-L1 were 41.7% and 45.8%, respectively. TLR4 expression was closely associated with PD-L1 expression. The expression of TLR4 was closely related to primary extranodal site involvement, increased Ann Arbor stage, and low hemoglobin expression, while the expression of PD-L1 was closely related to a low platelet count and multiple extranodal organ involvements (>1). High expression of either TLR4 or PD-L1 indicated a poor survival rate for patients with PTCL. Multivariate analyses further confirmed that increased expression levels of TLR4 and PD-L1 are unfavorable prognostic factors for PTCL.
Conclusion: This study demonstrates that the expressions of TLR4 and PD-L1 are independent predictors of survival time for patients with PTCL. Thus, TLR4 and PD-L1 may serve as potential therapeutic targets in PTCL patients.
Keywords: TLR4, PD-L1, peripheral T-cell lymphomas, non-Hodgkin’s lymphoma, immune checkpoint inhibitor, survival
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]